185525-49-9

Basic information

• Product Name: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one
• Synonyms: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one;Spiro[indene-2,4-piperidin]-1(3H)-one hydrochloride;SPIRO[INDENE-2,4-PIPERIDIN]-1(3H)-ONE HCL
• CAS NO: 185525-49-9
• Molecular Formula: C13H15NO
• Molecular Weight: 201.2643
• Mol File: 185525-49-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one(185525-49-9)
• EPA Substance Registry System: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one(185525-49-9)

Safety Data

• Hazardous Substances Data: 185525-49-9(Hazardous Substances Data)

Upstream product

• 1228079-29-5 tert-butyl 1-oxo-1,3-dihydrospiro[indene-2,4’-piperidine]-1’-carboxylate 

Downstream Products

• 1207163-36-7 C₂₆H₂₆N₄O₃ 

Relevant articles and documents

Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine]

Cyclization of the benzoylpiperidine in lead compound 2 generated a series of novel and highly potent spiropiperidine-based stearoyl-CoA desaturase (SCD)-1 inhibitors. Among them, 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine] (19) demonstrated the most powerful inhibitory activity against SCD-1, not only in vitro but also in vivo (C57BL/6 J mice). With regard to the pharmacological evaluation, 19 showed powerful reduction of the desaturation index in the plasma of C57BL/6 J mice on a non-fat diet after a 7-day oral administration (q.d.) without causing notable abnormalities in the eyes or skin up to the highest dose (3 mg/kg) in our preliminary analysis.

Spiro piperidines and homologs promote release of growth hormone

There are disclosed certain novel compounds identified as spiro piperidines and homologs which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such spiro compounds as the active ingredient thereof are also disclosed.